DNA and protein-generated chimeric molecules for delivery of influenza viral epitopes in mouse and humanized NSG transfer models

References

• Quiñones-Parra S, Clemens E, Wang Z, Croom H, Kedzierski L, McVernon J, Vijaykrishna D, Kedzierska K. A role of influenza virus exposure history in determining pandemic susceptibility and CD8+ T cell responses. J Virol. 2016;90(15):6936–12. doi:10.1128/JVI.00349-16.
   PubMed Web of Science ®Google Scholar
• Zimmer S, Burke D. Historical perspective — Emergence of influenza A (H1N1) viruses. N Engl J Med. 2009;361(3):279–285. doi:10.1056/NEJMra0904322.
   PubMed Web of Science ®Google Scholar
• Hause BM, Collin EA, Liu R, Huang B, Sheng Z, Lu W, Wang D, Nelson EA, Li F. Characterization of a novel influenza virus in cattle and swine: proposal for a new genus in the Orthomyxoviridae family. MBio. 2014;5(2):e00031–e14. doi:10.1128/mBio.00031-14.
   PubMed Web of Science ®Google Scholar
• Ruiz M, Puig A, Bassols M, Fraile L, Armengol R. Influenza D virus: a review and update of its role in bovine respiratory syndrome. Viruses. 2022;14(12):2717. doi:10.3390/v14122717.
   PubMed Web of Science ®Google Scholar
• Krammer F, Smith G, Fouchier R, Peiris M, Kedzierska K, Doherty PC, Palese P, Shaw ML, Treanor J, Webster RG, et al. Influenza. Nat Rev Dis Primers. 2018;4(1): Article number: 3. doi:10.1038/s41572-018-0002-y.
   PubMedGoogle Scholar
• Mishra AC, Chadha MS, Choudhary ML, Potdar VA. Pandemic influenza (H1N1) 2009 is associated with severe disease in India. PLoS ONE. 2010;5:e10540. doi:10.1371/journal.pone.0010540.
   PubMedGoogle Scholar
• Guthmiller J, Wilson P. Harnessing immune history to combat influenza viruses. Curr Opin Immunol. 2018;53:187–95. doi:10.1016/j.coi.2018.05.010.
   PubMed Web of Science ®Google Scholar
• Wilson JR, Guo Z, Reber A, Kamal RP, Music N, Gansebom S, Bai Y, Levine M, Carney P, Tzeng W-P, et al. An influenza a virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo. Antivir Res. 2016;135:48–55. doi:10.1016/j.antiviral.2016.10.001.
   PubMed Web of Science ®Google Scholar
• Sakai T, Nishimura SI, Naito T, Saito M. Influenza A virus hemagglutinin and neuraminidase act as novel motile machinery. Sci Rep. 2017;7(1):45043. doi:10.1038/srep45043.
   PubMedGoogle Scholar
• Pizzorno A, Padey B, Terrier O, Rosa-Calatrava M. Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy. Front Immunol. 2019. doi:10.3389/fimmu.2019.00531.
   Web of Science ®Google Scholar
• Tutykhina I, Esmagambetov I, Bagaev A, Pichugin A, Lysenko A, Shcherbinin D, Sedova E, Logunov D, Shmarov M, Ataullakhanov R, et al. Vaccination potential of B and T epitope-enriched NP and M2 against influenza a viruses from different clades and hosts. PLoS ONE. 2018;13(1):e0191574. doi:10.1371/journal.pone.0191574.
   PubMed Web of Science ®Google Scholar
• Weidenbacher P, Kim P. Protect, modify, deprotect (PMD): a strategy for creating vaccines to elicit antibodies targeting a specific epitope. Proc Natl Acad Sci. 2019;116(20):9947–9952. doi:10.1073/pnas.1822062116.
   PubMed Web of Science ®Google Scholar
• Guo C, Zhang H, Xie X, Liu Y, Sun L, Li H, Yu P, Hu H, Sun J, Li Y, et al. H1N1 influenza virus epitopes classified by monoclonal antibodies. Exp Ther Med. 2018;16:2001–7. doi:10.3892/etm.2018.6429.
   PubMed Web of Science ®Google Scholar
• Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem. 2010;285(37):28403–9. doi:10.1074/jbc.R110.129809.
   PubMed Web of Science ®Google Scholar
• Hamilton BS, Whittaker GR, Daniel S. Influenza virus-mediated membrane fusion: determinants of hemagglutinin fusogenic activity and experimental approaches for assessing virus fusion. Viruses. 2012;4(7):1144–68. doi:10.3390/v4071144.
   PubMed Web of Science ®Google Scholar
• Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014–2015 influenza season. Cell Rep. 2015;12(1):1–6. doi:10.1016/j.celrep.2015.06.005.
   PubMed Web of Science ®Google Scholar
• Mallajosyula VV, Citron M, Ferrara F, NJ T, Liang X, JA F, Varadarajan R. Hemagglutinin sequence conservation guided stem immunogen design from influenza a H3 subtype. Front Immunol. 2015;6:329. doi:10.3389/fimmu.2015.00329.
   PubMed Web of Science ®Google Scholar
• Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 2015;14(3):167–82. doi:10.1038/nrd4529.
   PubMed Web of Science ®Google Scholar
• Nagy Z, Rajnavolgyi E, Hollosi M, Tóth GK, Váradi G, Penke B, Tóth I, Horváth A, Gergely J, Kurucz I, et al. The intersubunit region of the influenza virus haemagglutinin is recognized by antibodies during infection. Scand J Immunol. 1994;40:281–91. doi:10.1111/j.1365-3083.1994.tb03464.x.
   PubMed Web of Science ®Google Scholar
• Rajnavolgyi E, Horvath A, Gogolak P, Tóth GK, Fazekas G, Fridkin M, Pecht I. Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites. Eur J Immunol. 1997;27:3105–14. doi:10.1002/eji.1830271205.
   PubMed Web of Science ®Google Scholar
• Ivanovska N, Tchorbanov A, Prechl J, Maximova V, Voynova E, Vassilev TL. Immunization with a DNA chimeric molecule encoding a hemagglutinin peptide and a scFv CD21-specific antibody fragment induces long-lasting IgM and CTL responses to influenza virus. Vaccine. 2006;24:1830–1837. doi:10.1016/j.vaccine.2005.10.029.
   PubMed Web of Science ®Google Scholar
• Prechl J, Tchorbanov A, Horvath A, Baiu DC, Hazenbos W, Rajnavölgyi É, Kurucz I, Capel PJA, Erdei A. Targeting of influenza epitopes to murine CR1/CR2 using single-chain antibodies. Immunopharmacol. 1999;42:159–65. doi:10.1016/S0162-3109(99)00025-9.
   PubMedGoogle Scholar
• Gesheva V, Idakieva K, Kerekov N, Nikolova K, Mihaylova N, Doumanova L, Tchorbanov A. Marine gastropod hemocyanins as adjuvants of non-conjugated bacterial and viral proteins. Fish And Shellfish Immunol. 2011;30(1):135–142. doi:10.1016/j.fsi.2010.09.018.
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol. 2005;175(2):633–9. doi:10.4049/jimmunol.175.2.633.
   PubMed Web of Science ®Google Scholar
• Porter KR, Raviprakash K. DNA vaccine delivery and improved immunogenicity. Curr Issues Mol Biol. 2017;22:129–38. doi:10.21775/cimb.022.129.
   PubMed Web of Science ®Google Scholar
• Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines. 2016;15(3):313–29. doi:10.1586/14760584.2016.1124762.
   PubMed Web of Science ®Google Scholar
• Song L, Xiong D, Kang X, Yang Y, Wang J, Guo Y, Xu H, Chen S, Peng D, Pan Z, et al. An avian influenza a (H7N9) virus vaccine candidate based on the fusion protein of hemagglutinin globular head and salmonella typhimurium flagellin. BMC Biotechnol. 2015;15(1):79. doi:10.1186/s12896-015-0195-z.
   PubMedGoogle Scholar
• Wong TM, Ross TM. Use of computational and recombinant technologies for developing novel influenza vaccines. Expert Rev Vaccines. 2016;15(1):41–51. doi:10.1586/14760584.2016.1113877.
   PubMed Web of Science ®Google Scholar
• Berlanda Scorza F, Tsvetnitsky V, Donnelly JJ. Universal influenza vaccines: shifting to better vaccines. Vaccine. 2016;34(26):2926–33. doi:10.1016/j.vaccine.2016.03.085.
   PubMed Web of Science ®Google Scholar
• Carter DM, Darby CA, Lefoley BC, Crevar CJ, Alefantis T, Oomen R, Anderson SF, Strugnell T, Cortés-Garcia G, Vogel TU, et al. Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. J Virol. 2016;90(9):4720–34. doi:10.1128/JVI.03152-15.
   PubMed Web of Science ®Google Scholar
• Rice J, Ottensmeier C, Stevenson F. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8(2):108–20. doi:10.1038/nrc2326.
   PubMed Web of Science ®Google Scholar
• Grodeland G, Fredriksen AB, GÅ L, Vikse E, Fugger L, Bogen B. Antigen targeting to human HLA class II molecules increases efficacy of DNA vaccination. J Immunol. 2016;197:3575–85. doi:10.4049/jimmunol.1600893.
   PubMed Web of Science ®Google Scholar
• Barría MI, Garrido JL, Stein C, Scher E, Ge Y, Engel SM, Kraus TA, Banach D, Moran TM. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis. 2013;207:115–24. doi:10.1093/infdis/jis641.
   PubMed Web of Science ®Google Scholar
• Whittle JR, Wheatley AK, Wu L, Lingwood D, Kanekiyo M, Ma SS, Narpala SR, Yassine HM, Frank GM, Yewdell JW, et al. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple ig heavy-chain lineages. J Virol. 2014;88(8):4047–57. doi:10.1128/JVI.03422-13.
   PubMed Web of Science ®Google Scholar
• Yan J, Morrow MP, Chu JS, Racine T, Reed CC, Khan AS, Broderick KE, Kim JJ, Kobinger GP, Sardesai NY, et al. Broad cross- protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine. Vaccine. 2018;36(22):3079–89. doi:10.1016/j.vaccine.2017.09.086.
   PubMed Web of Science ®Google Scholar
• DeZure AD, Coates EE, Hu Z, Yamshchikov GV, Zephir KL, Enama ME, Plummer SH, Gordon IJ, Kaltovich F, Andrews S, et al. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. NPJ Vaccines. 2017;2:15. doi:10.1038/s41541-017-0016-6.
   PubMed Web of Science ®Google Scholar
• Stachyra A, Pietrzak M, Macioła A, Protasiuk A, Olszewska M, Śmietanka K, Minta Z, Góra-Sochacka A, Kopera E, Sirko A, et al. A prime/boost vaccination with HA DNA and pichia-produced HA protein elicits a strong humoral response in chickens against H5N1. Virus Res. 2017;232:41–7. doi:10.1016/j.virusres.2017.01.025.
   PubMed Web of Science ®Google Scholar
• Shibabaw T, Molla MD, Teferi B, Ayelign B. Role of IFN and complements system: innate immunity in SARS-CoV-2. J Inflamm Res. 2020;13:507–18. doi:10.2147/JIR.S267280.
   PubMed Web of Science ®Google Scholar
• Kranich J, Krautler N-J. How follicular dendritic cells shape the B-Cell antigenome. Front Immunol. 2016;7:225. doi:10.3389/fimmu.2016.00225.
   PubMed Web of Science ®Google Scholar
• Bennett K, Rooijakkers S, Gorham R. Let’s tie the knot: marriage of complement and adaptive immunity in pathogen evasion, for better or worse. Front Microbiol. 2017;8:89. doi:10.3389/fmicb.2017.00089.
   PubMed Web of Science ®Google Scholar
• García-García E, Rosales C. Fc receptor signaling in leukocytes: role in host defense and immune regulation. Curr Immunol Rev. 2009;5(3):227–42. doi:10.2174/157339509788921229.
   Google Scholar
• Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14:94–108. doi:10.1038/nri3582.
   PubMed Web of Science ®Google Scholar
• Zhong T-Y, Arancibia S, Born R, Tampe R, Villar J, Campo M, Manubens A, Becker MI. Hemocyanins stimulate innate immunity by inducing different temporal patterns of proinflammatory cytokine expression in macrophages. J Immunol. 2016;196(11):4650–4662. doi:10.4049/jimmunol.1501156.
   PubMed Web of Science ®Google Scholar
• Jiménez J, Salazar M, Arancibia S, Villar J, Salazar F, Brown G, Lavelle EC, Martínez-Pomares L, Ortiz-Quintero J, Lavandero S, et al. TLR4, but neither dectin-1 nor dectin-2, participates in the Mollusk hemocyanin-induced proinflammatory effects in antigen-presenting cells from mammals. Front Immunol. 2019;10:1136. doi:10.3389/fimmu.2019.01136.
   PubMed Web of Science ®Google Scholar
• Grødeland G, Fossum E, Bogen B. Polarizing T and B cell responses by APC-Targeted subunit vaccines. Front Immunol. 2015;6:367. doi:10.3389/fimmu.2015.00367.
   PubMed Web of Science ®Google Scholar
• Gesheva V, Chausheva S, Stefanova N, Mihaylova N, Doumanova L, Idakieva K, Tchorbanov A. Helix pomatia hemocyanin - a novel bio-adjuvant for viral and bacterial antigens. Int Immunopharmacol. 2015;26(1):162–168. doi:10.1016/j.intimp.2015.03.011.
   PubMed Web of Science ®Google Scholar
• Gong YM, Wei XF, Zheng YY, Li Y, Yu Q, Li PF, Zhu B, Schultz-Cherry S. Combining phage display technology with in silico-designed epitope vaccine to elicit robust antibody responses against emerging pathogen tilapia lake virus. J Virol. 2023;97(4):e0005023. doi:10.1128/jvi.00050-23.
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Yeap S, Ali A, Ho W-Y, Noorjahan B, Hamid M. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:1–15. doi:10.1155/2012/980250.
   Google Scholar
• Satheeshkumar PK. Expression of single chain variable fragment (scFv) molecules in plants: a comprehensive update. Mol Biotechnol. 2020;62(3):151–67. doi:10.1007/s12033-020-00241-3.
   PubMed Web of Science ®Google Scholar
• Sarker A, Rathore AS, Gupta RD. Evaluation of scFv protein recovery from E. coli by in vitro refolding and mild solubilization process. Microb Cell Fact. 2019;18:5. doi:10.1186/s12934-019-1053-9.
   PubMed Web of Science ®Google Scholar
• Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:980250. doi:10.1155/2012/980250.
   PubMed Web of Science ®Google Scholar
• Yusakul G, Sakamoto S, Pongkitwitoon B, Tanaka H, Morimoto S. Effect of linker length between variable domains of single chain variable fragment antibody against daidzin on its reactivity. Biosci Biotechnol Biochem. 2016;80(7):1306–12. doi:10.1080/09168451.2016.1156482.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Ohtoyo M, Wada E, Kato Y, Mano N, Goto J. Generation of a single-chain Fv fragment for the monitoring of deoxycholic acid residues anchored on endogenous proteins. Steroids. 2005;70(4):285–94. doi:10.1016/j.steroids.2004.11.012.
   PubMed Web of Science ®Google Scholar
• Dai K, Zhu H, Ruan C. Generation and characterization of recombinant single chain Fv antibody that recognizes platelet glycoprotein Ibα. Thromb Res. 2003;109(2–3):137–44. doi:10.1016/S0049-3848(03)00152-X.
   PubMed Web of Science ®Google Scholar
• Sakai K, Shimizu Y, Chiba T, Matsumoto-Takasaki A, Kusada Y, Zhang W, Nakata M, Kojima N, Toma K, Takayanagi A, et al. Isolation and characterization of phage-displayed single chain antibodies recognizing nonreducing terminal mannose residues. 1. A new strategy for generation of anti-carbohydrate antibodies. Biochemistry. 2007;46(1):253–62. doi:10.1021/bi061875e.
   PubMed Web of Science ®Google Scholar
• Liang GQ, Liu J, Zhou XX, Lin ZX, Chen T, Chen G, Wei H. Anti-CXCR4 single-Chain variable fragment antibodies have anti-tumor activity. Front Oncol. 2020;10:571194. doi:10.3389/fonc.2020.571194. PMID: 33392074; PMCID: PMC7775505.
   PubMed Web of Science ®Google Scholar
• Rajput R, Sharma G, Rawat V, Gautam A, Kumar B, Pattnaik B, Pradhan HK, Khanna M. Diagnostic potential of recombinant {scFv} antibodies generated against hemagglutinin protein of influenza A virus. Front Immunol. 2015;6. doi:10.3389/fimmu.2015.00440.
   PubMed Web of Science ®Google Scholar
• Herati RS, Wherry EJ. What is the predictive value of animal models for vaccine efficacy in humans? Consideration of strategies to improve the value of animal models. Cold Spring Harb Perspect Biol. 2018;10(4):a031583. doi:10.1101/cshperspect.a031583.
   PubMed Web of Science ®Google Scholar
• Krishnakumar V, Durairajan SSK, Alagarasu K, Li M, Dash AP. Recent updates on mouse models for human immunodeficiency, influenza, and dengue viral infections. Viruses. 2019;11(3):252. doi:10.3390/v11030252.
   PubMed Web of Science ®Google Scholar
• Lai F, Chen Q. Humanized mouse models for the study of infection and pathogenesis of human viruses. Viruses. 2018;10(11):643. doi:10.3390/v10110643. PMID: 30453598; PMCID: PMC6266013.
   PubMed Web of Science ®Google Scholar
• Theocharides AP, Rongvaux A, Fritsch K, Flavell RA, Manz MG. Humanized hemato-lymphoid system mice. Haematologica. 2016;101(1):5–19. doi:10.3324/haematol.2014.115212.
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, Watanabe T, Akashi K, Shultz LD, Harada M. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice. Blood. 2005;106(5):1565–73. doi:10.1182/blood-2005-02-0516.
   PubMed Web of Science ®Google Scholar
• Brehm MA, Bortell R, Verma M, Shultz LD, Greiner DL. Chapter 11 - Humanized mice in translational immunology. In: Tan SL, editors. Translational immunology. Academic Press; 2016. p. 285–326. doi:10.1016/B978-0-12-801577-3.00012-5.
   Google Scholar
• Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012;12(11):786–98. doi:10.1038/nri3311.
   PubMed Web of Science ®Google Scholar
• Walsh N, Kenney L, Jangalwe S, Aryee KE, Greiner DL, Brehm MA, Shultz LD. Humanized mouse models of clinical disease. Annu Rev Pathol. 2017;12(1):187–215. doi:10.1146/annurev-pathol-052016-100332.
   PubMedGoogle Scholar
• Sasaki E, Momose H, Hiradate Y, Furuhata K, Mizukami T, Hamaguchi I. Development of a preclinical humanized mouse model to evaluate acute toxicity of an influenza vaccine. Oncotarget. 2018;9(40):25751. doi:10.18632/oncotarget.25399.
   PubMedGoogle Scholar
• Dadonaite B, Gilbertson B, Knight ML, Trifkovic S, Rockman S, Laederach A, Brown LE, Fodor E, Bauer DLV. The structure of the influenza a virus genome. Nature Microbiology. 2019;4(11):1781–1789. doi:10.1038/s41564-019-0513-7.
   PubMed Web of Science ®Google Scholar
• Kerekov N, Ivanova I, Mihaylova N, Nikolova M, Prechl J, Tchorbanov A. Built-in adjuvanticity of genetically and protein engineered chimeric molecules for targeting of influenza a peptide epitopes. Immunol Research. 2014;60(1):23–34. doi:10.1007/s12026-014-8489-0.
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Takeda J, Hong K, Kozono H, Sakai H, Inoue K. Monoclonal antibodies to mouse complement receptor type 1 (CR1): their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. J Immunol. 1988;140:3066. doi:10.4049/jimmunol.140.9.3066.
   PubMedGoogle Scholar
• Tchorbanov A, Voynova E, Mihaylova N, Todorov T, Nikolova M, Yomtova VM, Chiang B-L, Vassilev T. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur J Immunol. 2007;37:3587–3596. doi:10.1002/eji.200737143.
   PubMed Web of Science ®Google Scholar
• Gesheva V, Chausheva S, Stefanova N, Mihaylova N, Doumanova L, Idakieva K, Tchorbanov A. Helix pomatia hemocyanin - a novel bio-adjuvant for viral and bacterial antigens. Int Immunopharmacol. 2015;1:162–8. doi:10.1016/j.intimp.2015.03.011. Epub 2015 Mar 20. PMID: 25799956.
   Google Scholar
• Ivanova I, Mihaylova N, Manoylov I, Makatsori D, Lolov S, Nikolova M, Mamalaki A, Prechl J, Tchorbanov A. Targeting of Influenza viral epitopes to antigen presenting cells by Genetically Engineered Chimeric Molecules in Humanized NSG transfer model. Hum Gene Ther. 2018;29:(9):1056–1070. doi:10.1089/hum.2018.100.
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine. 2008;26:D41–4. doi:10.1016/j.vaccine200807043.
   PubMed Web of Science ®Google Scholar
• Xenopoulos A, Pattnaik P. Production and purification of plasmid DNA vaccines: is there scope for further innovation? Expert Rev Vaccines. 2014;13(12):1537–51. doi:10.1586/14760584.2014.968556.
   PubMed Web of Science ®Google Scholar
• Gerdts V, Wilson HL, Meurens F, Van Drunen Littel-Van Den Hurk S, Wilson D, Walker S, Wheler C, Townsend H, Potter AA. Large animal models for vaccine development and testing. ILAR J. 2015;56:53. doi:10.1093/ilar/ilv009.
   PubMed Web of Science ®Google Scholar
• Klenerman P, Zinkernagel R. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature. 1998;394(6692):482–5. doi:10.1038/28860.
   PubMed Web of Science ®Google Scholar
• Bot A, Isobe H, Bona C. Immunodeficient mouse models in the characterization of the protective immunity to influenza virus. Folia Microbiol. 1998;43(5):477–8. doi:10.1007/BF02820795.
   PubMed Web of Science ®Google Scholar
• Brumeanu TD, Casares S, Harris PE, Dehazya P, Wolf I, von Boehmer H, Bona CA. Immunopotency of a viral peptide assembled on the carbohydrate moieties of self immunoglobulins. Nat Biotechnol. 1996;14(6):722–5. doi:10.1038/nbt0696-722. PMID: 9630978.
   PubMed Web of Science ®Google Scholar
• Zaghouani H, Steinman R, Nonacs R, Shah H, Gerhard W, Bona C. Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Sci. 1993;259(5092):224–7. doi:10.1126/science.7678469. PMID: 7678469.
   PubMed Web of Science ®Google Scholar
• Casares S, Brumeanu TD, Bot A, Bona CA. Protective immunity elicited by vaccination with DNA encoding for a B cell and a T cell epitope of the A/PR/8/34 influenza virus. Viral Immunol. 1997;10(3):129–36. PMID: 9344335. doi: 10.1089/vim.1997.10.129.
   PubMed Web of Science ®Google Scholar
• Bot A, Antohi S, Bot S, Garcia-Sastre A, Bona C. Induction of humoral and cellular immunity against influenza virus by immunization of newborn mice with a plasmid bearing a hemagglutinin gene. Int Immunol. 1997;9(11):1641–50. doi: 10.1093/intimm/9.11.1641. PMID: 9418125.
   PubMed Web of Science ®Google Scholar
• Brumeanu TD, Bot A, Bona CA, Dehazya P, Wolf I, Zaghouani H. Engineering of doubly antigenized immunoglobulins expressing T and B viral epitopes. Immunotechnology. 1996;2(2):85–95. doi:10.1016/1380-2933(96)85196-7. PMID: 9373317.
   PubMedGoogle Scholar
• Li SQ, Schulman JL, Moran T, Bona C, Palese P. Influenza a virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes. J Virol. 1992;66(1):399–404. doi:10.1128/JVI.66.1.399-404.1992. PMID: 1370088; PMCID: PMC238299.
   PubMed Web of Science ®Google Scholar
• Bot A, Reichlin A, Isobe H, Bot S, Schulman J, Yokoyama WM, Bona CA. Cellular mechanisms involved in protection and recovery from influenza virus infection in immunodeficient mice. J Virol. 1996;70(8):5668–72. doi:10.1128/JVI.70.8.5668-5672.1996. PMID: 8764086; PMCID: PMC190532.
   PubMed Web of Science ®Google Scholar
• Kirchenbaum GA, Ross TM. Eliciting broadly protective antibody responses against influenza. Curr Opin Immunol. 2014;28:71–6. doi:10.1016/j.coi.2014.02.005.
   PubMed Web of Science ®Google Scholar
• Nussing S, Sant, S., Koutsakos, M., Subbarao, K., Nguyen, T.H.O., Kedzierska, K. Innate and adaptive T cells in influenza disease. Front Med. 2018;12(1):34–47. doi:10.1007/s11684-017-0606-8.
   PubMed Web of Science ®Google Scholar
• Liao HY, Wang SC, Ko YA, Lin KI, Ma C, Cheng TR, Wong CH. Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes. Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17757–17763. doi:10.1073/pnas.2004783117. Epub 2020. PMID: 32669430; PMCID: PMC7395492.
   PubMed Web of Science ®Google Scholar
• Puente-Massaguer E, Vasilev K, Beyer A, Loganathan M, Francis B, Scherm MJ, Arunkumar GA, González-Domínguez I, Zhu X, Wilson IA, et al. Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice. Sci Adv. 2023;9(37):eadi4753. doi:10.1126/sciadv.adi4753. Epub 2023 Sep 13. PMID: 37703367; PMCID: PMC10499326.
   PubMed Web of Science ®Google Scholar
• Nachbagauer R, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Stadlbauer D, Wilson PC, Aydillo T, et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2021;27(1):106–14. doi:10.1038/s41591-020-1118-7.
   PubMed Web of Science ®Google Scholar
• Puente-Massaguer E, Beyer A, Loganathan M, Sapse I, Carreño JM, Bajic G, Sun W, Palese P, Krammer F. Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses. Front Bioeng Biotechnol. 2023;11:1097349. doi:10.3389/fbioe.2023.1097349. PMID: 37342504; PMCID: PMC10277804.
   PubMed Web of Science ®Google Scholar
• Carroll MC. The complement system in B cell regulation. Mol Immunol. 2004;41(2–3):141–6. doi:10.1016/j.molimm.2004.03.017.
   PubMed Web of Science ®Google Scholar
• Molina H, Holers VM, Li B, Fang Y-F, Mariathasan S, Goellner J, Strauss-Schoenberger J, Karr RW, Chaplin DD. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci U S A. 1996;93:3357. doi:10.1073/pnas.93.8.3357.
   PubMed Web of Science ®Google Scholar
• Saha R, Killian S, Robert D. DNA vaccines: a mini review. Recent patents on DNA & gene sequences. 2011;5(2):92–96. doi:10.2174/187221511796392114.
   Google Scholar
• Carter DM, Darby CA, Johnson SK, Carlock MA, Kirchenbaum GA, DiNapoli J, Vogel TU, Delagrave S, DiNapoli J, Kleanthous H, et al. Elicitation of protective antibodies against a broad panel of H1N1 viruses in ferrets pre-immune to historical H1N1 influenza viruses. J Virol. 2017;91. doi:10.1128/JVI.01283-17.
   Web of Science ®Google Scholar
• Crevar CJ, Carter DM, Lee KY, Ross TM. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades. Hum Vaccin Immunother. 2015;11(3):572–83. doi:10.1080/21645515.2015.1012013.
   PubMed Web of Science ®Google Scholar